Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × penpulimab × Clear all

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Pheochromocytoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Paraganglioma, Extra-Adrenal 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma Metastatic 1 Osteosarcoma 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Lymphoma 1 Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1 Gynecological Cancer 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Esophageal Squamous Cell Carcinoma 1 Digestive System Diseases 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1 Breast Neoplasm Female 1

Interventions

Cyclophosphamide 272 Rituximab 243 Etoposide 136 Filgrastim 128 fludarabine phosphate 105 Cytarabine 98 Vincristine 97 Radiotherapy 96 Melphalan 95 Doxorubicin 90 Peripheral Blood Stem Cell Transplantation 82 Methotrexate 80 fludarabine 78 Prednisone 78 Busulfan 77 Tacrolimus 54 Whole-Body Irradiation 52 Mycophenolic Acid 52 Granulocyte Colony-Stimulating Factor 52 Dexamethasone 52 Antilymphocyte Serum 51 Carmustine 49 Cyclosporine 39 Lenalidomide 38 Methylprednisolone 37 Bortezomib 37 Bendamustine Hydrochloride 34 sargramostim 33 Stem Cell Transplantation 31 Ifosfamide 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05680038 2023-01-11

Penpulimab in Maintenance Therapy in Lymphoma

The First Affiliated Hospital with Nanjing Medical University

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡